In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Alizyme plc

Hyloris Raises €15m In Private Equity Offering

Value-added medicines firm Hyloris has raised €15m from new and existing investors through a private equity offering of nearly one million new shares.

Financing Value-Added Medicines

Why Has Japan Launched A $420m Fund For Bioventures?

A new national project to support bioventures and the venture capital funds investing in them has started in Japan. The strategic aim of the JPY50bn initiative is to enhance the speed of development and trials of new drugs and vaccines for infectious diseases, the lack of which became obvious since the breakout of COVID-19. 

Japan Innovation

Hyloris Outlines Ambitious Growth Strategy During Full-Year Results

Hyloris expects to expand its portfolio to around 30 candidates by 2024, bolstered by €50m in cash and cash equivalents as of the end of 2021.

Sales & Earnings Strategy

CohBar’s First Mitochondria Based Therapy Shows Promise In NASH

The first clinical results from its mitochondrial derived peptide pipeline is good news for CohBar, but it needs investors or big pharma partners to help it progress.

Liver & Hepatic Metabolic Disorders
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register